Get Live Data
Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Trademark Approval

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.15
Bid: 2.10
Ask: 2.19
Change: 0.035 (1.66%)
Spread: 0.09 (4.286%)
Open: 2.06
High: 2.15
Low: 2.06
Prev. Close: 2.11
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trademark Approval

13 May 2008 06:00

RNS Number : 2381U
Immupharma PLC
13 May 2008
 



For Immediate Release

13 May 2008

ImmuPharma PLC

Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today that it received approval of its trademark name LUPUZOR TM for its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark Office.
 

 

Immupharma has selected the trademark LUPUZOR TM for use in association with its peptide therapy for treating immunological disorders, including systemic lupus erythematosus (SLE). An application for reserving the right to use the LUPUZOR TM trademark was filed, and has now been allowed by the United States Patent and Trademark Office (Serial No. 77239130).

Dimitri Dimitriou, ImmuPharma’s CEO commented: “We believe LUPUZOR TM is a milestone in preparing for the commercialisation of our lead drug candidate for Lupus. The LUPUZOR TM brand will potentially facilitate the rapid market uptake of the compound by enabling a strong awareness from patients, physicians and healthcare organisations.”

 
LUPUZOR TM is currently undergoing a large Phase IIb clinical trial in Lupus patients in Europe and Latin America, results of which are expected later this year. LUPUZOR TM has already shown efficacy and safety in a small Phase II study in late 2006. LUPUZOR TM may reach the market in around two and a half years’ time, providing substantial revenues for the company.

 

For further information please contact: 

ImmuPharma PLC: 

 

Dimitri Dimitriou, Chief Executive Officer

+44 20 7152 4080

Dr Robert Zimmer, President & Chief Scientific Officer

+ 33 389 32 76 50

Richard Warr, Chairman

+44 20 7152 4080

 

 

Buchanan Communications

+ 44 20 7466 5000

Lisa Baderoon

 

Rebecca Skye Dietrich

 

 

 

Panmure Gordon & Co

 

Andrew Burnett

+44 151 243 0963

For company information, visit www.immupharma.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBKQPBKDNPD
12345678910
Date   Source Headline
30th Jul 20217:00 amRNSBoard Changes
16th Jul 20217:00 amRNSBoard Appointment
28th Jun 202112:27 pmRNS2021 RESULT OF ANNUAL GENERAL MEETING -REPLACEMENT
28th Jun 202111:03 amRNS2021 RESULT OF ANNUAL GENERAL MEETING
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUpdate: Lupzuor™ PK study
2nd Jun 20217:00 amRNSNotice of AGM and posting of Report & Accounts
24th May 20217:00 amRNSDirector Retirement
29th Apr 20214:35 pmRNSPrice Monitoring Extension
29th Apr 20217:00 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
25th Feb 20214:41 pmRNSSecond Price Monitoring Extn
25th Feb 20214:35 pmRNSPrice Monitoring Extension
9th Feb 20217:00 amRNSUpdate- scheduled Phase 3 trials in lupus patients
18th Jan 20217:00 amRNSAppointment of Company Secretary
4th Jan 20217:00 amRNSHolding(s) in Company
2nd Dec 20207:00 amRNSIMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
30th Nov 20207:00 amRNSTotal Share Capital Notification
26th Nov 20207:00 amRNSGrant of Share Options & PDMR dealing
24th Nov 20207:00 amRNSConversion of Convertible Security
23rd Nov 20207:00 amRNSConversion of Convertible Security
20th Nov 20207:00 amRNSUpdate : FDA confirms 4 Dec for Type ‘A’ meeting
18th Nov 20207:00 amRNSTotal Share Capital Notification - Replacement
10th Nov 20207:00 amRNSUpdate on submission to the FDA
30th Sep 20207:01 amRNSTotal Share Capital Notification
30th Sep 20207:00 amRNSInterim Results
29th Sep 20207:00 amRNSShare Subscription into Incanthera plc
22nd Sep 20207:00 amRNSRepayment of Convertible Security
11th Sep 20207:59 amRNSUpdate on submission to the FDA
10th Sep 202010:59 amRNSConversion of Convertible Security
9th Sep 20201:45 pmRNSConversion of Convertible Security
8th Sep 20203:49 pmRNSHolding(s) in Company
8th Sep 20209:00 amRNSDirector/PDMR Shareholding / TR -1
7th Sep 20207:02 amRNSPlacing - update; related party transaction)
3rd Sep 20207:00 amRNSConversion of Convertible Security
2nd Sep 20207:00 amRNSPlacing to raise £6.5 million
1st Sep 20207:00 amRNSHolding(s) in Company
27th Jul 20207:00 amRNSFDA submission for Special Protocol Assessment
18th Jun 202011:31 amRNS2020 AGM – ALL RESOLUTIONS PASSED
16th Jun 20207:00 amRNSTotal Share Capital Notification
11th Jun 202012:00 pmRNSTR-1 Notification of major holdings
11th Jun 20207:00 amRNSSTRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
5th Jun 20207:00 amRNSChange of Registered Office Address
2nd Jun 20207:00 amRNSNotification of Change of AGM Venue
21st May 20207:00 amRNSNotice of AGM and posting of Report & Accounts
18th May 20201:45 pmRNSTR-1: Notification of major holdings
14th May 20207:00 amRNSEfforts in fight vs Covid-19 with Lupuzor; Ureka
30th Apr 20209:57 amRNSAudited Report & Accounts published on website
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.